Phase II Multi-Centric, Randomised, Open-Label, Parallel-Group Study to Assess the Non-Inferiority of Pamorelin [triptorelin] 11,25mg SC [subcutaneous] Injected Versus Pamorelin 11,25mg IM [intramuscular] Injected in Patients Suffering From Advanced Prostate Cancer.

Trial Profile

Phase II Multi-Centric, Randomised, Open-Label, Parallel-Group Study to Assess the Non-Inferiority of Pamorelin [triptorelin] 11,25mg SC [subcutaneous] Injected Versus Pamorelin 11,25mg IM [intramuscular] Injected in Patients Suffering From Advanced Prostate Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms PAMOJECT
  • Sponsors Ipsen
  • Most Recent Events

    • 17 Dec 2009 Actual patient number (25) added as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 26 Jun 2008 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top